Minnelide, a novel drug for pancreatic and liver cancer
S Banerjee, A Saluja - Pancreatology, 2015 - Elsevier
Background Pancreatic cancer is the 10th leading cause of all new cancer cases for men
and the fourth leading cause of death across genders, having very poor prognosis and
survival rates. The current standard of care Gemcitabine fails to add any survival benefit for
this disease (www. cancer. gov). Though the incidence of pancreatic cancer is found to be
higher in developed countries, the aggressive biology of the cancer, its high rate of
recurrence and chemo-resistance make it a formidable disease in all parts of the globe …
and the fourth leading cause of death across genders, having very poor prognosis and
survival rates. The current standard of care Gemcitabine fails to add any survival benefit for
this disease (www. cancer. gov). Though the incidence of pancreatic cancer is found to be
higher in developed countries, the aggressive biology of the cancer, its high rate of
recurrence and chemo-resistance make it a formidable disease in all parts of the globe …
